Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors
Diabetes research and clinical practice, 2026;:113618
Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance
Pharmacoepidemiology and drug safety;35(11)
Starvation-associated high-anion gap metabolic acidosis following short-term oral semaglutide use: A case report
The Journal of international medical research, 2026;54(10):3000605261471333
Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12-Month Real-World Results
Diabetes, obesity & metabolism, 2026
Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats
Molecular metabolism, 2026;:102464
GLP-1 receptor activation attenuates chronic migraine-like behaviour: Sex-specific modulation of opioid- and endocannabinoid-related pathways
British journal of pharmacology, 2026
Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis
Medicine;105(43):e51306
Structural Mass Spectrometry Resolves the Conformational Dynamics of Semaglutide Oligomerization
Journal of the American Chemical Society;148(38):41169-41183
Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500
The Journal of the American Academy of Orthopaedic Surgeons, 2026
Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis
Diabetes care, 2026
Oral Health-Related Adverse Events of GLP-1 Receptor Agonists
JDR clinical and translational research, 2026;:23800844261491724
Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis
Diabetes, obesity & metabolism, 2026
Glucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study
Transplantation, 2026
GLP-1-Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection
Diabetes, obesity & metabolism, 2026
Interpreting Diabetic Retinal Outcomes After GLP-1 Receptor Agonist and Tirzepatide Initiation: Clinical Evidence and Its Limits
Diabetes, obesity & metabolism, 2026
Semaglutide for MASH in Japanese patients: findings consistent with the overall ESSENCE population
Journal of gastroenterology, 2026
The GLP-1 receptor agonist semaglutide reduces alcohol consumption and anxiety-like behaviors during withdrawal in Marchigian Sardinian alcohol-preferring rats
Neuropharmacology, 2026;:111240
GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis
Breast cancer research and treatment, 2026;220(1)
Characteristics and Treatment Utilisation Patterns of Individuals Using Tirzepatide for Type 2 Diabetes in Germany
Advances in therapy, 2026
[Efficacy and safety of domestic semaglutide injection in patients with type 2 diabetes mellitus inadequately controlled with metformin: a multicenter, randomized, controlled phase 3 equivalence clinical trial]
Zhonghua yi xue za zhi, 2026;106:4501-4512